Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according t...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2021-12, Vol.11 (12), p.192-192, Article 192
Main Authors: Fernández de Larrea, Carlos, Kyle, Robert, Rosiñol, Laura, Paiva, Bruno, Engelhardt, Monika, Usmani, Saad, Caers, Jo, Gonsalves, Wilson, Schjesvold, Fredrik, Merlini, Giampaolo, Lentzch, Suzanne, Ocio, Enrique, Garderet, Laurent, Moreau, Philippe, Sonneveld, Pieter, Badros, Ashraf, Gahrton, Gösta, Goldschmidt, Hartmut, Tuchman, Sascha, Einsele, Hermann, Durie, Brian, Wirk, Baldeep, Musto, Pellegrino, Hayden, Patrick, Kaiser, Martin, Miguel, Jesús San, Bladé, Joan, Rajkumar, S. Vincent, Mateos, Maria Victoria
Format: Article
Language:English
Subjects:
631/67/1990/804
631/67/68
631/80
Aged
Biomedical and Life Sciences
Biomedicine
Cancer Research
Female
Hematology
Human health and pathology
Human health sciences
Humans
Hématologie
Leukemia
Leukemia, Plasma Cell - diagnosis
Leukemia, Plasma Cell - pathology
Leukemia, Plasma Cell/diagnosis/pathology
Life Sciences
Male
Medicin och hälsovetenskap
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - pathology
Multiple Myeloma/diagnosis/pathology
Oncology
Plasma
Plasma Cells - pathology
Prognosis
Retrospective Studies
Sciences de la santé humaine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-021-00587-0